Interactions between osteopontin and vascular endothelial growth factor: Implications for cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1855, Issue 2, 2015, Pages 202-222

  Ramchandani, Divya ^a   Weber, Georg F ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Angiogenesis; Apoptosis; Cancer; Hypoxia; Immune system; Vascular disease

Indexed keywords

ALPHA1 INTERFERON; ANDROGRAPHOLIDE; ANTINEOPLASTIC AGENT; BERBAMINE; BIOLOGICAL MARKER; BORTEZOMIB; CA 125 ANTIGEN; CURCUMIN; CYCLOOXYGENASE 2; DEXAMETHASONE; ENDOGLIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LANG DU EXTRACT; MELPHALAN; OSTEOPONTIN; PAZOPANIB; PLANT EXTRACT; SG600 IL 24; SMALL INTERFERING RNA; SUNITINIB; THALIDOMIDE; TIRAPAZAMINE; TOPIRAMATE; UNCLASSIFIED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR; ZOLEDRONIC ACID; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ACUTE LEUKEMIA; ANGIOGENESIS; APOPTOSIS; ATHEROGENESIS; BRAIN TUMOR; BREAST CANCER; CANCER GENE THERAPY; CANCER GROWTH; CANCER PROGNOSIS; CELL MOTILITY; CELL PROTECTION; CHINESE MEDICINE; CHORIOANGIOMA; CHRONIC LYMPHATIC LEUKEMIA; DIABETIC RETINOPATHY; DIGESTIVE SYSTEM CANCER; FIBROSING ALVEOLITIS; GLUCOSE TRANSPORT; HEAD AND NECK CANCER; HUMAN; HYPOXIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; MELANOMA; MESOTHELIOMA; MULTIPLE MYELOMA; MYELOID LEUKEMIA; MYELOMA; NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION; PULMONARY TUMOR THROMBOTIC MICROANGIOPATHY; REVIEW; UPREGULATION; URINARY TRACT CANCER; UTERINE CERVIX CARCINOMA; VASCULAR DISEASE; ANTAGONISTS AND INHIBITORS; CELL HYPOXIA; CELL MOVEMENT; DRUG EFFECTS; GENETICS; INFLAMMATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL HYPOXIA; CELL MOVEMENT; INFLAMMATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOPONTIN; PROGNOSIS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84924256612     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.02.003     Document Type: Review

References (221)

1. Otsuru S., Tamai K., Yamazaki T., Yoshikawa H., Kaneda Y. Circulating bone marrow-derived osteoblast progenitor cells are recruited to the bone-forming site by the CXCR4/stromal cell-derived factor-1 pathway. Stem Cells 2008, 26:223-234.
2. Jäger M., Krauspe R. Antigen expression of cord blood derived stem cells under osteogenic stimulation in vitro. Cell Biol. Int. 2007, 31:950-957.
3. Sulzbacher I., Birner P., Trieb K., Lang S., Chott A. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch. 2002, 441:345-349.
4. Sando N., Oka K., Moriya T., Saito H., Nagakura S., Mori N., Suzuki T., Ueki H., Ohtani H. Osteosarcoma arising in the breast. APMIS 2006, 114:581-587.
5. Solberg T.D., Nearman J., Mullins J., Li S., Baranowska-Kortylewicz J. Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72:918-926.
6. Bache M., Reddemann R., Said H., Holzhausen H.-J., Taubert H., Becker A., Kuhnt T., Hänsgen G., Dunst J., Vordermark D. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66:1481-1487.
7. Hotta M., Ishida M., Kojima F., Iwai Y., Okabe H. Pulmonary tumor thrombotic microangiopathy caused by lung adenocarcinoma: case report with review of the literature. Oncol. Lett. 2011, 2:435-437.
8. Ishiwata T., Takahashi K., Shimanuki Y., Ohashi R., Cui R., Takahashi F., Shimizu K., Miura K., Fukuchi Y. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res. 2005, 25:489-495.
9. Moschos C., Porfiridis I., Psallidas I., Kollintza A., Stathopoulos G.T., Papiris S.A., Roussos C., Kalomenidis I. Osteopontin is upregulated in malignant and inflammatory pleural effusions. Respirology 2009, 14:716-722.
10. Nahar N.N., Missana L.R., Garimella R., Tague S.E., Anderson H.C. Matrix vesicles are carriers of bone morphogenetic proteins (BMPs), vascular endothelial growth factor (VEGF), and noncollagenous matrix proteins. J. Bone Miner. Metab. 2008, 26:514-519.
11. Chakraborty G., Jain S., Kundu G.C. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008, 68:152-161.
12. Raja R., Kale S., Thorat D., Soundararajan G., Lohite K., Mane A., Karnik S., Kundu G.C. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis. Oncogene 2014, 33:2053-2064.
13. Wahl V., Vogler S., Grosche A., Pannicke T., Ueffing M., Wiedemann P., Reichenbach A., Hauck S., Bringmann A. Osteopontin inhibits osmotic swelling of retinal glial (Müller) cells by inducing release of VEGF. Neuroscience 2013, 246:59-72.
14. Ootsuji H., Honda M., Kaneko S., Usui S., Okajima M., Okada H., Sakai Y., Takamura T., Horimoto K., Takamura M. Altered hepatic gene expression profiles associated with myocardial ischemia. Circ. Cardiovasc. Genet. 2010, 3:68-77.
15. Cui R., Takahashi F., Ohashi R., Yoshioka M., Gu T., Tajima K., Unnoura T., Iwakami S., Hirama M., Ishiwata T., Iwase A., Takahashi K. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer 2009, 63:368-374.
16. Dai J., Peng L., Fan K., Wang H., Wei R., Ji G., Cai J., Lu B., Li B., Zhang D., Kang Y., Tan M., Qian W., Guo Y. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 2009, 28:3412-3422.
17. Kohan M., Breuer R., Berkman N. Osteopontin induces airway remodeling and lung fibroblast activation in a murine model of asthma. Am. J. Respir. Cell Mol. Biol. 2009, 41:290-296.
18. Blasberg J.D., Goparaju C.M., Pass H.I., Donington J.S. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J. Thorac. Cardiovasc. Surg. 2010, 139:1587-1593.
19. Lazar M., Sullivan J., Chipitsyna G., Gong Q., Ng C.Y., Salem A.F., Aziz T., Witkiewicz A., Denhardt D.T., Yeo C.J., Arafat H.A. Involvement of osteopontin in the matrix-degrading and proangiogenic changes mediated by nicotine in pancreatic cancer cells. J. Gastrointest. Surg. 2010, 14:1566-1577.
20. Tilli T.M., Mello K.D., Ferreira L.B., Matos A.R., Accioly M.T., Faria P.A., Bellahcène A., Castronovo V., Gimba E.R. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 2012, 72:1688-1699.
21. Kumar S., Sharma P., Kumar D., Chakraborty G., Gorain M., Kundu G.C. Functional characterization of stromal osteopontin in melanoma progression and metastasis. PLoS One 2013, 8:e69116.
22. Li X.-D., Chen J., Ruan C.-C., Zhu D.-L., Gao P.-J. Vascular endothelial growth factor-induced osteopontin expression mediates vascular inflammation and neointima formation via Flt-1 in adventitial fibroblasts. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2250-2258.
23. Seipelt R.G., Backer C.L., Mavroudis C., Stellmach V., Cornwell M., Seipelt I.M., Schoendube F.A., Crawford S.E. Osteopontin expression and adventitial angiogenesis induced by local vascular endothelial growth factor 165 reduces experimental aortic calcification. J. Thorac. Cardiovasc. Surg. 2005, 129:773-781.
24. Infanger M., Shakibaei M., Kossmehl P., Hollenberg S., Grosse J., Faramarzi S., Schulze-Tanzil G., Paul M., Grimm D. Intraluminal application of vascular endothelial growth factor enhances healing of microvascular anastomosis in a rat model. J. Vasc. Res. 2005, 42:202-213.
25. Deng Y., Zhou H., Yan C., Wang Y., Xiao C., Gu P., Fan X. In vitro osteogenic induction of bone marrow stromal cells with encapsulated gene-modified bone marrow stromal cells and in vivo implantation for orbital bone repair. Tissue Eng. Part A 2014, 20:2019-2029.
26. Kärner E., Bäckesjö C.-M., Cedervall J., Sugars R., Ahrlund-Richter L., Wendel M. Dynamics of gene expression during bone matrix formation in osteogenic cultures derived from human embryonic stem cells in vitro. Biochim. Biophys. Acta 2009, 1790:110-118.
27. Ramazanoglu M., Lutz R., Rusche P., Trabzon L., Kose G.T., Prechtl C., Schlegel K.A. Bone response to biomimetic implants delivering BMP-2 and VEGF: an immunohistochemical study. J. Craniomaxillofac. Surg. 2013, 41:826-835.
28. Takano S., Tsuboi K., Tomono Y., Mitsui Y., Nose T. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br. J. Cancer 2000, 82:1967-1973.
29. Takano S., Yamashita T., Ohneda O. Molecular therapeutic targets for glioma angiogenesis. J. Oncol. 2010, 2010:351908.
30. Senger D.R., Ledbetter S.R., Claffey K.P., Papadopoulos-Sergiou A., Peruzzi C.A., Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am. J. Pathol. 1996, 149:293-305.
31. Han Y.-F., Cao G.-W. Role of nuclear receptor NR4A2 in gastrointestinal inflammation and cancers. World J. Gastroenterol. 2012, 18:6865-6873.
32. Infanger M., Grosse J., Westphal K., Leder A., Ulbrich C., Paul M., Grimm D. Vascular endothelial growth factor induces extracellular matrix proteins and osteopontin in the umbilical artery. Ann. Vasc. Surg. 2008, 22:273-284.
33. Leali D., Dell'Era P., Stabile H., Sennino B., Chambers A.F., Naldini A., Sozzani S., Nico B., Ribatti D., Presta M. Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J. Immunol. 2003, 171:1085-1093.
34. Soga N., Connolly J.O., Chellaiah M., Kawamura J., Hruska K.A. Rac regulates vascular endothelial growth factor stimulated motility. Cell Commun. Adhes. 2001, 8:1-13.
35. Infanger M., Ulbrich C., Baatout S., Wehland M., Kreutz R., Bauer J., Grosse J., Vadrucci S., Cogoli A., Derradji H., Neefs M., Küsters S., Spain M., Paul M., Grimm D. Modeled gravitational unloading induced downregulation of endothelin-1 in human endothelial cells. J. Cell. Biochem. 2007, 101:1439-1455.
36. Renault M.-A., Roncalli J., Tongers J., Thorne T., Klyachko E., Misener S., Volpert O.V., Mehta S., Burg A., Luedemann C., Qin G., Kishore R., Losordo D.W. Sonic hedgehog induces angiogenesis via Rho kinase-dependent signaling in endothelial cells. J. Mol. Cell. Cardiol. 2010, 49:490-498.
37. Wang Y., Yan W., Lu X., Qian C., Zhang J., Li P., Shi L., Zhao P., Fu Z., Pu P., Kang C., Jiang T., Liu N., You Y. Overexpression of osteopontin induces angiogenesis of endothelial progenitor cells via the avβ3/PI3K/AKT/eNOS/NO signaling pathway in glioma cells. Eur. J. Cell Biol. 2011, 90:642-648.
38. Lisi A., Ledda M., De Carlo F., Foletti A., Giuliani L., D'Emilia E., Grimaldi S. Calcium ion cyclotron resonance (ICR) transfers information to living systems: effects on human epithelial cell differentiation. Electromagn. Biol. Med. 2008, 27:230-240.
39. David V., Martin A., Hedge A.-M., Rowe P.S. Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology 2009, 150:4012-4023.
40. Klevesath M.B., Pantel K., Agbaje O., Provenzano E., Wishart G.C., Gough P., Pinder S.E., Duffy S., Purushotham A.D. Patterns of metastatic spread in early breast cancer. Breast 2013, 22:449-454.
41. Hag A.M., Pedersen S.F., Christoffersen C., Binderup T., Jensen M.M., Jørgensen J.T., Skovgaard D., Ripa R.S., Kjaer A. (18)F-FDG PET imaging of murine atherosclerosis: association with gene expression of key molecular markers. PLoS One 2012, 7:e50908.
42. Umar S., Nadadur R., Iorga A., Amjedi M., Matori H., Eghbali M. Cardiac structural and hemodynamic changes associated with physiological heart hypertrophy of pregnancy are reversed postpartum. J. Appl. Physiol. 1985, 113(2012):1253-1259.
43. Oliva F., Barisani D., Grasso A., Maffulli N. Gene expression analysis in calcific tendinopathy of the rotator cuff. Eur. Cell Mater. 2011, 21:548-557.
44. Song Y.R., You S.J., Lee Y.-M., Chin H.J., Chae D.-W., Oh Y.K., Joo K.W., Han J.S., Na K.Y. Activation of hypoxia-inducible factor attenuates renal injury in rat remnant kidney. Nephrol. Dial. Transplant. 2010, 25:77-85.
45. Bennett M., Czech K., Arend L., Witte D., Devarajan P., Potter S.S. Laser capture microdissection-microarray analysis of focal segmental glomerulosclerosis glomeruli. Nephron Exp. Nephrol. 2007, 107:30-40.
46. Sheibani N., Morrison M.E., Gurel Z., Park S., Sorenson C.M. BIM deficiency differentially impacts the function of kidney endothelial and epithelial cells through modulation of their local microenvironment. Am. J. Physiol. Ren. Physiol 2012, 302:809-819.
47. Min B.S., Kim N.K., Jeong H.C., Chung H.C. High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection. Oncol. Lett. 2012, 4:123-130.
48. Hardie W.D., Korfhagen T.R., Sartor M.A., Prestridge A., Medvedovic M., Le Cras T.D., Ikegami M., Wesselkamper S.C., Davidson C., Dietsch M., Nichols W., Whitsett J.A., Leikauf G.D. Genomic profile of matrix and vasculature remodeling in TGF-alpha induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2007, 37:309-321.
49. Gallot D., Marceau G., Laurichesse-Delmas H., Vanlieferinghen P., Dechelotte P.J., Lemery D., Sapin V. The changes in angiogenic gene expression in recurrent multiple chorioangiomas. Fetal Diagn. Ther. 2007, 22:161-168.
50. Tang H., Wang J., Bai F., Hong L., Liang J., Gao J., Zhai H., Lan M., Zhang F., Wu K., Fan D. Inhibition of osteopontin would suppress angiogenesis in gastric cancer. Biochem. Cell Biol. 2007, 85:103-110.
51. Takahashi F., Akutagawa S., Fukumoto H., Tsukiyama S., Ohe Y., Takahashi K., Fukuchi Y., Saijo N., Nishio K. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int. J. Cancer 2002, 98:707-712.
52. Kang D.H., Kim Y.G., Andoh T.F., Gordon K.L., Suga S., Mazzali M., Jefferson J.A., Hughes J., Bennett W., Schreiner G.F., Johnson R.J. Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor. Am. J Physiol. Ren. Physiol. 2001, 280:727-736.
53. Suzuki H., Hasegawa Y., Kanamaru K., Zhang J.H. Mechanisms of osteopontin-induced stabilization of blood-brain barrier disruption after subarachnoid hemorrhage in rats. Stroke 2010, 41:1783-1790.
54. Infanger M., Kossmehl P., Shakibaei M., Baatout S., Witzing A., Grosse J., Bauer J., Cogoli A., Faramarzi S., Derradji H., Neefs M., Paul M., Grimm D. Induction of three-dimensional assembly and increase in apoptosis of human endothelial cells by simulated microgravity: impact of vascular endothelial growth factor. Apoptosis 2006, 11:749-764.
55. Kang D.H., Hughes J., Mazzali M., Schreiner G.F., Johnson R.J. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J. Am. Soc. Nephrol. 2001, 12:1448-1457.
56. Ramchandani D., Weber G. Interactions between osteopontin and vascular endothelial growth factor: implications for skeletal disorders. Bone 2015, (Manuscript submitted).
57. Dudley A.C., Khan Z.A., Shih S.-C., Kang S.-Y., Zwaans B.M., Bischoff J., Klagsbrun M. Calcification of multipotent prostate tumor endothelium. Cancer Cell 2008, 14:201-211.
58. Burke D.L., Frid M.G., Kunrath C.L., Karoor V., Anwar A., Wagner B.D., Strassheim D., Stenmark K.R. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 297:238-250.
59. Foris V., Kovacs G., Tscherner M., Olschewski A., Olschewski H. Biomarkers in pulmonary hypertension: what do we know?. Chest 2013, 144:274-283.
60. Palenski T.L., Sorenson C.M., Sheibani N. Inflammatory cytokine-specific alterations in retinal endothelial cell function. Microvasc. Res. 2013, 89:57-69.
61. Gattorno M., Gregorio A., Ferlito F., Gerloni V., Parafioriti A., Felici E., Sala E., Gambini C., Picco P., Martini A. Synovial expression of osteopontin correlates with angiogenesis in juvenile idiopathic arthritis. Rheumatology (Oxford) 2004, 43:1091-1096.
62. Shijubo N., Uede T., Kon S., Maeda M., Segawa T., Imada A., Hirasawa M., Abe S. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am. J. Respir. Crit. Care Med. 1999, 160:1269-1273.
63. Takahashi F., Kumasaka T., Nagaoka T., Wakiya M., Fujii H., Shimizu K., Uchida K., Morio Y., Seyama K., Hino O., Takahashi K., Fukuchi Y. Osteopontin expression in pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma. Pathol. Int. 2009, 59:752-756.
64. Hatfield K.J., Bedringsaas S.L., Ryningen A., Gjertsen B.T., Bruserud Ø. Hypoxia increases HIF-1α expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. Eur. Cytokine Netw. 2010, 21:154-164.
65. Kumar S., Patil H.S., Sharma P., Kumar D., Dasari S., Puranik V.G., Thulasiram H.V., Kundu G.C. Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase/Akt signaling pathway. Curr. Mol. Med. 2012, 12:952-966.
66. Porat Y., Assa-Kunik E., Belkin M., Krakovsky M., Lamensdorf I., Duvdevani R., Sivak G., Niven M.J., Bulvik S. A novel potential therapy for vascular diseases: blood-derived stem/progenitor cells specifically activated by dendritic cells. Diabetes Metab. Res. Rev. 2014, 30:623-634.
67. Rowe G.C., Raghuram S., Jang C., Nagy J.A., Patten I.S., Goyal A., Chan M.C., Liu L.X., Jiang A., Spokes K.C., Beeler D., Dvorak H., Aird W.C., Arany Z. PGC-1α induces SPP1 to activate macrophages and orchestrate functional angiogenesis in skeletal muscle. Circ. Res. 2014, 115:504-517.
68. Fujita N., Fujita S., Okada Y., Fujita K., Kitano A., Yamanaka O., Miyamoto T., Kon S., Uede T., Rittling S.R., Denhardt D.T., Saika S. Impaired angiogenic response in the corneas of mice lacking osteopontin. Invest. Ophthalmol. Vis. Sci. 2010, 51:790-794.
69. Takagi H., Suzuma K., Otani A., Oh H., Koyama S., Ohashi H., Watanabe D., Ojima T., Suganami E., Honda Y. Role of vitronectin receptor-type integrins and osteopontin in ischemia-induced retinal neovascularization. Jpn. J. Ophthalmol. 2002, 46:270-278.
70. Fujita N., Fujita S., Ogata N., Matsuoka M., Okada Y., Kon S., Uede T., Saika S. Endogenous osteopontin involvement in laser-induced choroidal neovascularization in mice. Invest. Ophthalmol. Vis. Sci. 2011, 52:9310-9315.
71. Shin E.S., Sorenson C.M., Sheibani N. PEDF expression regulates the proangiogenic and proinflammatory phenotype of the lung endothelium. Am. J. Physiol. Lung Cell. Mol. Physiol. 2014, 306:620-634.
72. Fitzpatrick L.E., Chan J.W., Sefton M.V. On the mechanism of poly(methacrylic acid-co-methyl methacrylate)-induced angiogenesis: gene expression analysis of dTHP-1 cells. Biomaterials 2011, 32:8957-8967.
73. Vannini N., Roch A., Naveiras O., Griffa A., Kobel S., Lutolf M.P. Identification of in vitro HSC fate regulators by differential lipid raft clustering. Cell Cycle 2012, 11:1535-1543.
74. Hamada Y., Nokihara K., Okazaki M., Fujitani W., Matsumoto T., Matsuo M., Umakoshi Y., Takahashi J., Matsuura N. Angiogenic activity of osteopontin-derived peptide SVVYGLR. Biochem. Biophys. Res. Commun. 2003, 310:153-157.
75. Hamada Y., Yuki K., Okazaki M., Fujitani W., Matsumoto T., Hashida M., Harutsugu K., Nokihara K., Daito M., Matsuura N., Takahashi J. Osteopontin-derived peptide SVVYGLR induces angiogenesis in vivo. Dent. Mater. J. 2004, 23:650-655.
76. Kwasiborski P.J., Kowalczyk P., Mrówka P., Kwasiborski M., Cwetsch A., Przybylski J. Selected, biochemical markers of hypoxia. Przegl. Lek. 2012, 69:115-119.
77. Said H.M., Hagemann C., Staab A., Stojic J., Kühnel S., Vince G.H., Flentje M., Roosen K., Vordermark D. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother. Oncol. 2007, 83:398-405.
78. Vergis R., Corbishley C.M., Norman A.R., Bartlett J., Jhavar S., Michael B., Heeboll S., Horwich A., Huddart R., Khoo V., Eeles R., Cooper C., Sydes M., Dearnaley D., Pardker C. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol. 2008, 9:342-351.
79. Wu Y., Han X., Guo Y., Wu H., Ren J., Li J., Ai D., Wang L., Bai D. Response of immortalized murine cementoblast cells to hypoxia in vitro. Arch. Oral Biol. 2013, 58:1718-1725.
80. Bosco M.C., Delfino S., Ferlito F., Puppo M., Gregorio A., Gambini C., Gattorno M., Martini A., Varesio L. The hypoxic synovial environment regulates expression of vascular endothelial growth factor and osteopontin in juvenile idiopathic arthritis. J. Rheumatol. 2009, 36:1318-1329.
81. Potier E., Ferreira E., Andriamanalijaona R., Pujol J.-P., Oudina K., Logeart-Avramoglou D., Petite H. Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression. Bone 2007, 40:1078-1087.
82. Li Z.-H., Liao W., Zhao Q., Huan T., Feng P., Wei X., Yi Y., Shao N.-S. Effect of Cbfa1 on osteogenic differentiation of mesenchymal stem cells under hypoxia condition. Int. J. Clin. Exp. Med. 2014, 7:540-548.
83. Wu C., Zhou Y., Chang J., Xiao Y. Delivery of dimethyloxallyl glycine in mesoporous bioactive glass scaffolds to improve angiogenesis and osteogenesis of human bone marrow stromal cells. Acta Biomater. 2013, 9:9159-9168.
84. Bandopadhyay M., Bulbule A., Butti R., Chakraborty G., Ghorpade P., Ghosh P., Gorain M., Kale S., Kumar D., Kumar S., Totakura K., Roy G., Sharma P., Shetti D., Soundararajan G., Thorat D., Tomar D., Nalukurthi R., Raja R., Mishra R., Yadav A., Kundu G. Osteopontin as a therapeutic target for cancer. Expert Opin. Ther. Targets 2014, 18:883-895.
85. Yang L., Zhao W., Zuo W.-S., Wei L., Song X.-R., Wang X.-W., Zheng G., Zheng M.-Z. Silencing of osteopontin promotes the radiosensitivity of breast cancer cells by reducing the expression of hypoxia inducible factor 1 and vascular endothelial growth factor. Chin. Med. J. (Engl.) 2012, 125:293-299.
86. Jang A., Hill R.P. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. Clin. Exp. Metastasis 1997, 15:469-483.
87. Sahai S., Williams A., Skiles M.L., Blanchette J.O. Osteogenic differentiation of adipose-derived stem cells is hypoxia-inducible factor-1 independent. Tissue Eng. Part A 2013, 19:1583-1591.
88. Paranjpe A., Cacalano N.A., Hume W.R., Jewett A. N-Acetylcysteine protects dental pulp stromal cells from HEMA-induced apoptosis by inducing differentiation of the cells. Free Radic. Biol. Med. 2007, 43:1394-1408.
89. Infanger M., Kossmehl P., Shakibaei M., Cogoli A., Witzing A., Faramarzi S., Wittfoht W., Paul M., Grimm D. Vascular endothelial growth factor inhibits programmed cell death of endothelial cells induced by clinorotation. J. Gravit. Physiol. 2004, 11:199-200.
90. Gyorffy B., Surowiak P., Budczies J., Lánczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 2013, 8:e82241.
91. Ostheimer C., Bache M., Güttler A., Kotzsch M., Vordermark D. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor. Strahlenther. Onkol. 2014, 190:276-282.
92. Mack P.C., Redman M.W., Chansky K., Williamson S.K., Farneth N.C., Lara P.N.J., Franklin W.A., Le Q.-T., Crowley J.J., Gandara D.R., SWOG Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J. Clin. Oncol. 2008, 26:4771-4776.
93. Masuzaki R., Karp S.J., Omata M. New serum markers of hepatocellular carcinoma. Semin. Oncol. 2012, 39:434-439.
94. Zaravinos A., Volanis D., Lambrou G.I., Delakas D., Spandidos D.A. Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder. Oncol. Rep. 2012, 28:1159-1166.
95. Wang H.-L., Ruan L.-H., Zhao X.-Q. Expression of osteopontin and VEGF in acute leukemia and their relationship with angiogenesis. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011, 19:926-929.
96. Sfiridaki A., Miyakis S., Pappa C., Tsirakis G., Alegakis A., Kotsis V., Stathopoulos E., Alexandrakis M. Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma. J. Hematol. Oncol. 2011, 4:22.
97. Valković T., Babarović E., Lučin K., Stifter S., Aralica M., Pećanić S., Seili-Bekafigo I., Duletić-Načinović A., Nemet D., Jonjić N. Plasma levels of osteopontin and vascular endothelial growth factor in association with clinical features and parameters of tumor burden in patients with multiple myeloma. Biomed. Res. Int. 2014, 2014:513170.
98. Piersma S.R., Fiedler U., Span S., Lingnau A., Pham T.V., Hoffmann S., Kubbutat M.H., Jiménez C.R. Workflow comparison for label-free, quantitative secretome proteomics for cancer biomarker discovery: method evaluation, differential analysis, and verification in serum. J. Proteome Res. 2010, 9:1913-1922.
99. Tang H., Wang J., Bai F., Zhai H., Gao J., Hong L., Xie H., Zhang F., Lan M., Yao W., Liu J., Wu K., Fan D. Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer. Cancer Invest. 2008, 26:60-67.
100. Tahara E. Molecular aspects of invasion and metastasis of stomach cancer. Verh. Dtsch. Ges. Pathol. 2000, 84:43-49.
101. Byers L.A., Holsinger F.C., Kies M.S., William W.N., El-Naggar A.K., Lee J.J., Hu J., Lopez A., Tran H.T., Yan S., Du Z., Ang K., Glisson B.S., Raso M.G., Wistuba I.I., Myers J.N., Hong W.-K., Papadimitrakopoulou V., Lippman S.M., Heymach J.V. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol. Cancer Ther. 2010, 9:1755-1763.
102. Nishimori H., Yasoshima T., Hata F., Denno R., Yanai Y., Nomura H., Tanaka H., Kamiguchi K., Sato N., Hirata K. A novel nude mouse model of liver metastasis and peritoneal dissemination from the same human pancreatic cancer line. Pancreas 2002, 24:242-250.
103. Tang Z.-Y., Ye S.-L., Liu Y.-K., Qin L.-X., Sun H.-C., Ye Q.-H., Wang L., Zhou J., Qiu S.-J., Li Y., Ji X.-N., Liu H., Xia J.-L., Wu Z.-Q., Fan J., Ma Z.-C., Zhou X.-D., Lin Z.-Y., Liu K.-D. A decade's studies on metastasis of hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2004, 130:187-196.
104. Psallidas I., Stathopoulos G.T., Maniatis N.A., Magkouta S., Moschos C., Karabela S.P., Kollintza A., Simoes D.C., Kardara M., Vassiliou S., Papiris S.A., Roussos C., Kalomenidis I. Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion. Oncogene 2013, 32:528-535.
105. Qin L.-X., Tang Z.-Y. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J. Cancer Res. Clin. Oncol. 2004, 130:497-513.
106. Tanaka Y., Abe M., Hiasa M., Oda A., Amou H., Nakano A., Takeuchi K., Kitazoe K., Kido S., Inoue D., Moriyama K., Hashimoto T., Ozaki S., Matsumoto T. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin. Cancer Res. 2007, 13:816-823.
107. Edelmann J., Klein-Hitpass L., Carpinteiro A., Führer A., Sellmann L., Stilgenbauer S., Dührsen U., Dürig J. Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells. Leuk. Res. 2008, 32:1565-1572.
108. Ma B., Pan Y., Song Q., Tie L., Zhang Y., Xiao Y., Zhang J., Han J., Xu Y., Xiang Y., Yu H.-M., Li X.-J. The effect of topiramate on tumor-related angiogenesis and on the serum proteome of mice bearing Lewis lung carcinoma. Eur. J. Pharmacol. 2011, 663:9-16.
109. Mi Z., Guo H., Kuo P.C. Identification of osteopontin-dependent signaling pathways in a mouse model of human breast cancer. BMC Res. Notes 2009, 2:119.
110. Wang Z.-M., Cui Y.-H., Li W., Chen S.-Y., Liu T.-S. Lentiviral-mediated siRNA targeted against osteopontin suppresses the growth and metastasis of gastric cancer cells. Oncol. Rep. 2011, 25:997-1003.
111. Wu X.-L., Lin K.-J., Bai A.-P., Wang W.-X., Meng X.-K., Su X.-L., Hou M.-X., Dong P.-D., Zhang J.-J., Wang Z.-Y., Shi L. Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells. World J. Gastroenterol. 2014, 20:10440-10448.
112. Chakraborty G., Jain S., Kale S., Raja R., Kumar S., Mishra R., Kundu G.C. Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol. Med. Rep. 2008, 1:641-646.
113. Tong X., Li K., Luo Z., Lu B., Liu X., Wang T., Pang M., Liang B., Tan M., Wu M., Zhao J., Guo Y. Decreased TIP30 expression promotes tumor metastasis in lung cancer. Am. J. Pathol. 2009, 174:1931-1939.
114. Kwak T.-k., Sohn E., Kim S., Won G., Choi J.-U., Jeong K., Jeong M., Kwon O., Kim S.-H. Inhibitory effect of ethanol extract of Ocimum sanctum on osteopontin mediated metastasis of NCI-H460 non-small cell lung cancer cells. BMC Complement. Altern. Med. 2014, 14:419.
115. Ray M., Kindler H.L. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 2009, 136:888-896.
116. Wang S., Liu Q., Zhang Y., Liu K., Yu P., Liu K., Luan J., Duan H., Lu Z., Wang F., Wu E., Yagasaki K., Zhang G. Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action. Mol. Cancer 2009, 8:81.
117. Minai-Tehrani A., Jiang H.-L., Kim Y.-K., Chung Y.-S., Yu K.-N., Kim J.-E., Shin J.-Y., Hong S.-H., Lee J.-H., Kim H.-J., Chang S.-H., Park S., Kang B.N., Cho C.-S., Cho M.-H. Suppression of tumor growth in xenograft model mice by small interfering RNA targeting osteopontin delivery using biocompatible poly(amino ester). Int. J. Pharm. 2012, 431:197-203.
118. Rosen D.G., Wang L., Atkinson J.N., Yu Y., Lu K.H., Diamandis E.P., Hellstrom I., Mok S.C., Liu J., Bast R.C.J. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol. Oncol. 2005, 99:267-277.
119. Fredriksson S., Horecka J., Brustugun O.T., Schlingemann J., Koong A.C., Tibshirani R., Davis R.W. Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer. Clin. Chem. 2008, 54:582-589.
120. Lu K.H., Patterson A.P., Wang L., Marquez R.T., Atkinson E.N., Baggerly K.A., Ramoth L.R., Rosen D.G., Liu J., Hellstrom I., Smith D., Hartmann L., Fishman D., Berchuck A., Schmandt R., Whitaker R., Gershenson D.M., Mills G.B., Bast R.C.J. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 2004, 10:3291-3300.
121. Jacob F., Goldstein D.R., Fink D., Heinzelmann-Schwarz V. Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs. Biomark. Med 2009, 3:743-756.
122. Li R., Qiao J., Wang L., Li L., Zhen X., Liu P., Zheng X. MicroRNA array and microarray evaluation of endometrial receptivity in patients with high serum progesterone levels on the day of hCG administration. Reprod. Biol. Endocrinol. 2011, 9:29.
123. Wong Y.-F., Cheung T.-H., Tsao G.S., Lo K.W., Yim S.-F., Wang V.W., Heung M.M., Chan S.C., Chan L.K., Ho T.W., Wong K.W., Li C., Guo Y., Chung T.K., Smith D.I. Genome-wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray. Int. J. Cancer 2006, 118:2461-2469.
124. Isebaert S., Haustermans K., Van den Bergh L., Joniau S., Dirix P., Oyen R., Deroose C.M., Van Poppel H., Lerut E. Identification and characterization of nodal metastases in prostate cancer patients at high risk for lymph node involvement. Acta Oncol. 2013, 52:1336-1344.
125. Akech J., Wixted J.J., Bedard K., van der Deen M., Hussain S., Guise T.A., van Wijnen A.J., Stein J.L., Languino L.R., Altieri D.C., Pratap J., Keller E., Stein G.S., Lian J.B. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010, 29:811-821.
126. Su B., Zheng Q., Vaughan M.M., Bu Y., Gelman I.H. SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition. Cancer Res. 2006, 66:5599-5607.
127. Shoji S., Nakano M., Sato H., Tang X.Y., Osamura Y.R., Terachi T., Uchida T., Takeya K. The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma. Clin. Exp. Metastasis 2014, 31:111-134.
128. Zurita A.J., Jonasch E., Wang X., Khajavi M., Yan S., Du D.Z., Xu L., Herynk M.H., McKee K.S., Tran H.T., Logothetis C.J., Tannir N.M., Heymach J.V. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann. Oncol. 2012, 23:46-52.
129. Yao L., Liu F., Hong L., Sun L., Liang S., Wu K., Fan D. The function and mechanism of COX-2 in angiogenesis of gastric cancer cells. J. Exp. Clin. Cancer Res. 2011, 30:13.
130. Abe H., Hino R., Fukayama M. Platelet-derived growth factor-A and vascular endothelial growth factor-C contribute to the development of pulmonary tumor thrombotic microangiopathy in gastric cancer. Virchows Arch. 2013, 462:523-531.
131. Okubo Y., Wakayama M., Kitahara K., Nemoto T., Yokose T., Abe F., Hiruta N., Sasai D., Shinozaki M., Nakayama H., Ishiwatari T., Shibuya K. Pulmonary tumor thrombotic microangiopathy induced by gastric carcinoma: morphometric and immunohistochemical analysis of six autopsy cases. Diagn. Pathol. 2011, 6:27.
132. Catalán V., Gómez-Ambrosi J., Rodríguez A., Ramírez B., Silva C., Rotellar F., Hernández-Lizoain J.L., Baixauli J., Valentí V., Pardo F., Salvador J., Frühbeck G. Up-regulation of the novel proinflammatory adipokines lipocalin-2, chitinase-3 like-1 and osteopontin as well as angiogenic-related factors in visceral adipose tissue of patients with colon cancer. J. Nutr. Biochem. 2011, 22:634-641.
133. Viana L.S., Affonso R.J., Silva S.R., Denadai M.V., Matos D., Salinas de Souza C., Waisberg J. Relationship between the expression of the extracellular matrix genes SPARC, SPP1, FN1, ITGA5 and ITGAV and clinicopathological parameters of tumor progression and colorectal cancer dissemination. Oncology 2013, 84:81-91.
134. Zekri A.-R.N., Bahnassy A.A., Alam El-Din H.M., Morsy H.M., Shaarawy S., Moharram N.Z., Daoud S.S. Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma. Oncol. Rep. 2011, 26:825-831.
135. Quiles-Perez R., Muñoz-Gámez J.A., Ruiz-Extremera A., O'Valle F., Sanjuán-Nuñez L., Martín-Alvarez A.B., Martín-Oliva D., Caballero T., Muñoz de Rueda P., León J., Gonzalez R., Muntané J., Oliver F.J., Salmerón J. Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. Hepatology 2010, 51:255-266.
136. Wang C.-J., Xiao C.-W., You T.-G., Zheng Y.-X., Gao W., Zhou Z.-Q., Chen J., Xue X.-B., Fan J., Zhang H. Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma. Mol. Cancer 2012, 11:31.
137. Sedivy R., Kalipciyan M., Mazal P.R., Wolf B., Wrba F., Karner-Hanusch J., Mühlbacher F., Mader R.M. Osteoclast-like giant cell tumor in mucinous cystadenocarcinoma of the pancreas: an immunohistochemical and molecular analysis. Cancer Detect. Prev. 2005, 29:8-14.
138. Yamaguchi Y., Shao Z., Sharif S., Du X.-Y., Myles T., Merchant M., Harsh G., Glantz M., Recht L., Morser J., Leung L.L. Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage. J. Biol. Chem. 2013, 288:3097-3111.
139. Manjila S., Miller E., Awadallah A., Murakami S., Cohen M., Cohen A. Ossified choroid plexus papilloma of the fourth ventricle: elucidation of the mechanism of osteogenesis in benign brain tumors. J. Neurosurg. Pediatr. 2013, 12:13-20.
140. Aderhold C., Grobschmidt G., Sauter A., Faber A., Hörmann K., Schultz J. Interleukin 4, interleukin 6 and osteopontin-serological markers of head and neck malignancy in primary diagnostics: a pilot study. Oncol. Lett. 2014, 8:1112-1118.
141. Kappler M., Taubert H., Holzhausen H.-J., Reddemann R., Rot S., Becker A., Kuhnt T., Dellas K., Dunst J., Vordermark D., Hänsgen G., Bache M. Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer. Prognostic role and correlation with tumor markers and tumor oxygenation parameters. Strahlenther. Onkol. 2008, 184:393-399.
142. Liu W., Li Z., Luo Q., Lai Y., Zhang J., Chen F., Shi J., Li H., Xiong G., Xu G., Wang H. The elevated expression of osteopontin and vascular endothelial growth factor in sinonasal inverted papilloma and its relationship with clinical severity. Am. J. Rhinol. Allergy 2011, 25:313-317.
143. Elias E.G., Hasskamp J.H., Sharma B.K. Cytokines and growth factors expressed by human cutaneous melanoma. Cancers (Basel) 2010, 2:794-808.
144. Wang L., Duan H., Wang Y., Liu K., Jiang P., Qu Z., Yagasaki K., Zhang G. Inhibitory effects of lang-du extract on the in vitro and in vivo growth of melanoma cells and its molecular mechanisms of action. Cytotechnology 2010, 62:357-366.
145. Khanna C., Prehn J., Yeung C., Caylor J., Tsokos M., Helman L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin. Exp. Metastasis 2000, 18:261-271.
146. Dass C.R., Choong P.F. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol. Cancer Ther. 2007, 6:3263-3270.
147. Matsumoto T., Abe M. Bone destruction in multiple myeloma. Ann. N. Y. Acad. Sci. 2006, 1068:319-326.
148. Abe M. Link between osteoclastogenesis, angiogenesis and myeloma expansion. Clin. Calcium 2008, 18:473-479.
149. Terpos E., Kastritis E., Roussou M., Heath D., Christoulas D., Anagnostopoulos N., Eleftherakis-Papaiakovou E., Tsionos K., Croucher P., Dimopoulos M.A. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008, 22:2247-2256.
150. Kou G., Shi J., Chen L., Zhang D., Hou S., Zhao L., Fang C., Zheng L., Zhang X., Liang P., Zhang X., Li B., Guo Y. A bispecific antibody effectively inhibits tumor growth and metastasis by simultaneous blocking vascular endothelial growth factor A and osteopontin. Cancer Lett. 2010, 299:130-136.
151. Ebos J.M., Lee C.R., Christensen J.G., Mutsaers A.J., Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17069-17074.
152. Liu Y., Starr M.D., Brady J.C., Dellinger A., Pang H., Adams B., Theuer C.P., Lee N.Y., Hurwitz H.I., Nixon A.B. Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. Cancer Med. 2014, 3:580-591.
153. Borensztajn K., Crestani B., Kolb M. Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers-insights from the bench side. Respiration 2013, 86:441-452.
154. Abu El-Asrar A., Nawaz M., De Hertogh G., Alam K., Siddiquei M., Van den Eynde K., Mousa A., Mohammad G., Geboes K., Opdenakker G. S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis. Mol. Vis. 2014, 20:1209-1224.
155. Grutzmacher C., Park S., Zhao Y., Morrison M.E., Sheibani N., Sorenson C.M. Aberrant production of extracellular matrix proteins and dysfunction in kidney endothelial cells with a short duration of diabetes. Am. J. Physiol. Ren. Physiol. 2013, 304:19-30.
156. Ahimastos A., Latouche C., Natoli A., Reddy-luthmoodoo M., Golledge J., Kingwell B. Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication. Circ. Res. 2014, 114:1144-1155.
157. Sanchez C., Deberg M.A., Bellahcène A., Castronovo V., Msika P., Delcour J.P., Crielaard J.M., Henrotin Y.E. Phenotypic characterization of osteoblasts from the sclerotic zones of osteoarthritic subchondral bone. Arthritis Rheum. 2008, 58:442-455.
158. Rajamannan N.M., Nealis T.B., Subramaniam M., Pandya S., Stock S.R., Ignatiev C.I., Sebo T.J., Rosengart T.K., Edwards W.D., McCarthy P.M., Bonow R.O., Spelsberg T.C. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation 2005, 111:3296-3301.
159. Silva R.A., Almeida F.M., Olivo C.R., Saraiva-Romanholo B.M., Martins M.A., Carvalho C.R. Airway remodeling is reversed by aerobic training in a murine model of chronic asthma. Scand. J. Med. Sci. Sports 2015 Feb 4, [Epub ahead of print]. 10.1111/sms.12411.
160. Ragno S., Romano M., Howell S., Pappin D.J., Jenner P.J., Colston M.J. Changes in gene expression in macrophages infected with Mycobacterium tuberculosis: a combined transcriptomic and proteomic approach. Immunology 2001, 104:99-108.
161. Gnainsky Y., Granot I., Aldo P.B., Barash A., Or Y., Schechtman E., Mor G., Dekel N. Local injury of the endometrium induces an inflammatory response that promotes successful implantation. Fertil. Steril. 2010, 94:2030-2036.
162. Watanabe M., Uchida K., Nakagaki K., Kanazawa H., Trapnell B.C., Hoshino Y., Kagamu H., Yoshizawa H., Keicho N., Goto H., Nakata K. Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 2007, 581:2017-2021.
163. Blum A., Zarqh O., Peleg A., Sirchan R., Blum N., Salameh Y., Ganaem M. Vascular inflammation and endothelial dysfunction in fracture healing. Am. J. Orthop. (Belle Mead NJ) 2012, 41:87-91.
164. Kuroda S., Virdi A.S., Dai Y., Shott S., Sumner D.R. Patterns and localization of gene expression during intramembranous bone regeneration in the rat femoral marrow ablation model. Calcif. Tissue Int. 2005, 77:212-225.
165. Kidd L.J., Stephens A.S., Kuliwaba J.S., Fazzalari N.L., Wu A.C., Forwood M.R. Temporal pattern of gene expression and histology of stress fracture healing. Bone 2010, 46:369-378.
166. Toti P., Sbordone C., Martuscelli R., Califano L., Ramaglia L., Sbordone L. Gene clustering analysis in human osteoporosis disease and modifications of the jawbone. Arch. Oral Biol. 2013, 58:912-929.
167. Hu Z.M., Peel S.A., Ho S.K., Sándor G.K., Clokie C.M. Role of bovine bone morphogenetic proteins in bone matrix protein and osteoblast-related gene expression during rat bone marrow stromal cell differentiation. J. Craniofac. Surg. 2005, 16:1006-1014.
168. Sueyoshi T., Yamamoto K., Akiyama H. Conditional deletion of Tgfbr2 in hypertrophic chondrocytes delays terminal chondrocyte differentiation. Matrix Biol. 2012, 31:352-359.
169. Chung E., Rylander M.N. Response of preosteoblasts to thermal stress conditioning and osteoinductive growth factors. Cell Stress Chaperones 2012, 17:203-214.
170. Li Z., Liao W., Zhao Q., Liu M., Xia W., Yang Y., Shao N. Angiogenesis and bone regeneration by allogeneic mesenchymal stem cell intravenous transplantation in rabbit model of avascular necrotic femoral head. J. Surg. Res. 2013, 183:193-203.
171. Hu Z.M., Peel S.A., Ho S.K., Sándor G.K., Clokie C.M. Comparison of platelet-rich plasma, bovine BMP, and rhBMP-4 on bone matrix protein expression in vitro. Growth Factors 2009, 27:280-288.
172. Zhou Y., Guan X., Yu M., Wang X., Zhu W., Wang C., Yu M., Wang H. Angiogenic/osteogenic response of BMMSCs on bone-derived scaffold: effect of hypoxia and role of PI3K/Akt-mediated VEGF-VEGFR pathway. Biotechnol. J. 2014, 9:944-953.
173. Caron M.M., Emans P.J., Coolsen M.M., Voss L., Surtel D.A., Cremers A., van Rhijn L.W., Welting T.J. Redifferentiation of dedifferentiated human articular chondrocytes: comparison of 2D and 3D cultures. Osteoarthr. Cart 2012, 20:1170-1178.
174. Huang W., Carlsen B., Wulur I., Rudkin G., Ishida K., Wuc B., Yamaguchia D.T., Miller T.A. BMP-2 exerts differential effects on differentiation of rabbit bone marrow stromal cells grown in two-dimensional and three-dimensional systems and is required for in vitro bone formation in a PLGA scaffold. Exp. Cell Res. 2004, 299:325-334.
175. Henderson J.A., He X., Jabbari E. Concurrent differentiation of marrow stromal cells to osteogenic and vasculogenic lineages. Macromol. Biosci. 2008, 8:499-507.
176. Huang C.K., Huang W., Zuk P., Jarrahy R., Rudkin G.H., Ishida K., Yamaguchi D.T., Miller T.A. Genetic markers of osteogenesis and angiogenesis are altered in processed lipoaspirate cells when cultured on three-dimensional scaffolds. Plast. Reconstr. Surg. 2008, 121:411-423.
177. Kreke M.R., Sharp L.A., Lee Y.W., Goldstein A.S. Effect of intermittent shear stress on mechanotransductive signaling and osteoblastic differentiation of bone marrow stromal cells. Tissue Eng. Part A 2008, 14:529-537.
178. Kim K., Dean D., Wallace J., Breithaupt R., Mikos A.G., Fisher J.P. The influence of stereolithographic scaffold architecture and composition on osteogenic signal expression with rat bone marrow stromal cells. Biomaterials 2011, 32:3750-3763.
179. Pedrosa W.F.J., Okamoto R., Faria P.E., Arnez M.F., Xavier S.P., Salata L.A. Immunohistochemical, tomographic and histological study on onlay bone graft remodeling. Part II: calvarial bone. Clin. Oral Implants Res. 2009, 20:1254-1264.
180. Faria P.E., Okamoto R., Bonilha-Neto R.M., Xavier S.P., Santos A.C., Salata L.A. Immunohistochemical, tomographic and histological study on onlay iliac grafts remodeling. Clin. Oral Implants Res. 2008, 19:393-401.
181. Verket A., Tiainen H., Haugen H.J., Lyngstadaas S.P., Nilsen O., Reseland J.E. Enhanced osteoblast differentiation on scaffolds coated with TiO2 compared to SiO2 and CaP coatings. Biointerphases 2012, 7:36.
182. Popp J.R., Laflin K.E., Love B.J., Goldstein A.S. In vitro evaluation of osteoblastic differentiation on amorphous calcium phosphate-decorated poly(lactic-co-glycolic acid) scaffolds. J. Tissue Eng. Regen. Med. 2011, 5:780-789.
183. Barron M., Goldman J., Tsai C.-J., Donahue S. Perfusion flow enhances osteogenic gene expression and the infiltration of osteoblasts and endothelial cells into three-dimensional calcium phosphate scaffolds. Int. J. Biomater. 2012, 2012:915620.
184. Wu C., Zhou Y., Xu M., Han P., Chen L., Chang J., Xiao Y. Copper-containing mesoporous bioactive glass scaffolds with multifunctional properties of angiogenesis capacity, osteostimulation and antibacterial activity. Biomaterials 2013, 34:422-433.
185. Hofmann A., Konrad L., Gotzen L., Printz H., Ramaswamy A., Hofmann C. Bioengineered human bone tissue using autogenous osteoblasts cultured on different biomatrices. J. Biomed. Mater. Res. A 2003, 67:191-199.
186. He J., Genetos D.C., Leach J.K. Osteogenesis and trophic factor secretion are influenced by the composition of hydroxyapatite/poly(lactide-co-glycolide) composite scaffolds. Tissue Eng. Part A 2010, 16:127-137.
187. Perrier A., Dumas V., Linossier M.T., Fournier C., Jurdic P., Rattner A., Vico L., Guignandon A. Apatite content of collagen materials dose-dependently increases pre-osteoblastic cell deposition of a cement line-like matrix. Bone 2010, 47:23-33.
188. Ozeki M., Kuroda S., Kon K., Kasugai S. Differentiation of bone marrow stromal cells into osteoblasts in a self-assembling peptide hydrogel: in vitro and in vivo studies. J. Biomater. Appl. 2011, 25:663-684.
189. Pham Q.P., Kurtis F.K., Scott Baggett L., Raphael R.M., Jansen J.A., Mikos A.G. The influence of an in vitro generated bone-like extracellular matrix on osteoblastic gene expression of marrow stromal cells. Biomaterials 2008, 29:2729-2739.
190. Pullisaar H., Reseland J.E., Haugen H.J., Brinchmann J.E., Ostrup E. Simvastatin coating of TiO2 scaffold induces osteogenic differentiation of human adipose tissue-derived mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2014, 447:139-144.
191. Xu L.-Y., Sun X.-J., Zhang X.-L., Jin Y.-Q., Wu Y.-Q., Jiang X.-Q. Repair of calvarial defect using a tissue-engineered bone with simvastatin-loaded β-tricalcium phosphate scaffold and adipose derived stem cells in rabbits. Shanghai Kou Qiang Yi Xue 2013, 22:361-367.
192. Lozano D., Trejo C.G., Gómez-Barrena E., Manzano M., Doadrio J.C., Salinas A.J., Vallet-Regí M., García-Honduvilla N., Esbrit P., Buján J. Osteostatin-loaded onto mesoporous ceramics improves the early phase of bone regeneration in a rabbit osteopenia model. Acta Biomater. 2012, 8:2317-2323.
193. Pacicca D.M., Patel N., Lee C., Salisbury K., Lehmann W., Carvalhoa R., Gerstenfelda L.C., Einhorn T.A. Expression of angiogenic factors during distraction osteogenesis. Bone 2003, 33:889-898.
194. Bhatt K., Chang E., Warren S., Lin S.-e., Bastidas N., Ghali S., Thibboneir A., Capla J., McCarthy J., Gurtner G. Uniaxial mechanical strain: an in vitro correlate to distraction osteogenesis. J. Surg. Res. 2007, 143:329-336.
195. Fang T.D., Nacamuli R.P., Song H.M., Fong K.D., Warren S.M., Salim A., Carano R.A., Filvaroff E.H., Longaker M.T. Creation and characterization of a mouse model of mandibular distraction osteogenesis. Bone 2004, 34:1004-1012.
196. Sharp L.A., Lee Y.W., Goldstein A.S. Effect of low-frequency pulsatile flow on expression of osteoblastic genes by bone marrow stromal cells. Ann. Biomed. Eng. 2009, 37:445-453.
197. Gleizal A., Ferreira S., Lavandier B., Simon B., Béziat J.L., Béra J.C. The impact of low intensity pulsed ultrasound on mouse skull bone osteoblast cultures. Rev. Stomatol. Chir. Maxillofac. 2010, 111:280-285.
198. Wu C., Zhai D., Ma H., Li X., Zhang Y., Zhou Y., Luo Y., Wang Y., Xiao Y., Chang J. Stimulation of osteogenic and angiogenic ability of cells on polymers by pulsed laser deposition of uniform akermanite-glass nanolayer. Acta Biomater. 2014, 10:3295-3306.
199. Chung E., Sampson A., Rylander M.N. Influence of heating and cyclic tension on the induction of heat shock proteins and bone-related proteins by MC3T3-E1 cells. Biomed. Res. Int. 2014, 2014:354260.
200. Kim I.S., Song J.K., Zhang Y.L., Lee T.H., Cho T.H., Song Y.M., Kim D.K., Kim S.J., Hwang S.J. Biphasic electric current stimulates proliferation and induces VEGF production in osteoblasts. Biochim. Biophys. Acta 2006, 1763:907-916.
201. Boonyagul S., Banlunara W., Sangvanich P., Thunyakitpisal P. Effect of acemannan, an extracted polysaccharide from aloe vera, on BMSCs proliferation, differentiation, extracellular matrix synthesis, mineralization, and bone formation in a tooth extraction model. Odontology 2014, 102:310-317.
202. Huh J.-E., Yang H.-R., Park D.-S., Choi D.-Y., Baek Y.-H., Cho E.-M., Cho Y.-J., Kang-Il K., Kim D.-Y., Lee J.-D. Puerariae radix promotes differentiation and mineralization in human osteoblast-like SaOS-2 cells. J. Ethnopharmacol. 2006, 104:345-350.
203. Huh J.-E., Kwon N.-H., Baek Y.-H., Lee J.-D., Choic D.-Y., Jingushid S., Kime K.-I., Park D.-S. Formononetin promotes early fracture healing through stimulating angiogenesis by up-regulating VEGFR-2/Flk-1 in a rat fracture model. Int. Immunopharmacol. 2009, 9:1357-1365.
204. Paglia D.N., Wey A., Breitbart E.A., Faiwiszewski J., Mehta S.K., Al-Zube L., Vaidya S., Cottrell J.A., Graves D., Benevenia J., O'Connor J.P., Lin S.S. Effects of local insulin delivery on subperiosteal angiogenesis and mineralized tissue formation during fracture healing. J. Orthop. Res. 2013, 31:783-791.
205. Kuo T.-F., Lin H.-C., Yang K.-C., Lin F.-H., Chen M.-H., Wu C.-C., Chang H.-H. Bone marrow combined with dental bud cells promotes tooth regeneration in miniature pig model. Artif. Organs 2011, 35:113-121.
206. Shima H., Matsuzaka K., Kokubu E., Inoue T. Regenerative capability of dental pulp cells after crown fracture. Dent. Traumatol. 2013, 29:29-33.
207. Koshihara T., Matsuzaka K., Sato T., Inoue T. Effect of stretching force on the cells of epithelial rests of Malassez in vitro. Int. J. Dent. 2010, 2010:458408.
208. Yamawaki K., Matsuzaka K., Kokubu E., Inoue T. Effects of epidermal growth factor and/or nerve growth factor on Malassez's epithelial rest cells in vitro: expression of mRNA for osteopontin, bone morphogenetic protein 2 and vascular endothelial growth factor. J. Periodontal Res. 2010, 45:421-427.
209. Takeda K., Shiba H., Mizuno N., Hasegawa N., Mouri Y., Hirachi A., Yoshino H., Kawaguchi H., Kurihara H. Brain-derived neurotrophic factor enhances periodontal tissue regeneration. Tissue Eng. 2005, 11:1618-1629.
210. Mangano C., Paino F., d'Aquino R., De Rosa A., Iezzi G., Piattelli A., Laino L., Mitsiadis T., Desiderio V., Mangano F., Papaccio G., Tirino V. Human dental pulp stem cells hook into biocoral scaffold forming an engineered biocomplex. PLoS One 2011, 6:e18721.
211. Miron R.J., Bosshardt D.D., Zhang Y., Buser D., Sculean A. Gene array of primary human osteoblasts exposed to enamel matrix derivative in combination with a natural bone mineral. Clin. Oral Investig. 2013, 17:405-410.
212. Koike Y., Murakami S., Matsuzaka K., Inoue T. The effect of Emdogain on ectopic bone formation in tubes of rat demineralized dentin matrix. J. Periodontal Res. 2005, 40:385-394.
213. Brott D.A., Adler S.H., Arani R., Lovick S.C., Pinches M., Furlong S.T. Characterization of renal biomarkers for use in clinical trials: biomarker evaluation in healthy volunteers. Drug Des. Dev. Ther. 2014, 8:227-237.
214. Steger-Hartmann T., Raschke M., Riefke B., Pietsch H., Sieber M.A., Walter J. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp. Toxicol. Pathol. 2009, 61:537-552.
215. Yazdani S., Poosti F., Kramer A.B., Mirković K., Kwakernaak A.J., Hovingh M., Slagman M.C., Sjollema K.A., de Borst M.H., Navis G., van Goor H., van den Born J. Proteinuria triggers renal lymphangiogenesis prior to the development of interstitial fibrosis. PLoS One 2012, 7:e50209.
216. Lin Y., Manning P.T., Jia J., Gaut J.P., Xiao Z., Capoccia B.J., Chen C.C., Hiebsch R.R., Upadhya G., Mohanakumar T., Frazier W.A., Chapman W.C. CD47 blockade reduces ischemia-reperfusion injury and improves outcomes in a rat kidney transplant model. Transplantation 2014, 98:394-401.
217. Hoffmann D., Fuchs T.C., Henzler T., Matheis K.A., Herget T., Dekant W., Hewitt P., Mally A. Evaluation of a urinary kidney biomarker panel in rat models of acute and subchronic nephrotoxicity. Toxicology 2010, 277:49-58.
218. Mazali F.C., Johnson R.J., Mazzali M. Use of uric acid-lowering agents limits experimental cyclosporine nephropathy. Nephron Exp. Nephrol. 2012, 120:e12-e19.
219. Fuchs T.C., Mally A., Wool A., Beiman M., Hewitt P. An exploratory evaluation of the utility of transcriptional and urinary kidney injury biomarkers for the prediction of aristolochic acid-induced renal injury in male rats. Vet. Pathol. 2014, 51:680-694.
220. Ertilav M., Timur O., Hür E., Bozkurt D., Nar H., Kologlu T., Sen S., Duman S. What does the dialysate level of matrix metalloproteinase 2 tell us?. Adv. Perit. Dial. 2011, 27:6-10.
221. Grimm D., Bauer J., Ulbrich C., Westphal K., Wehland M., Infanger M., Aleshcheva G., Pietsch J., Ghardi M., Beck M., El-Saghire H., de Saint-Georges L., Baatout S. Different responsiveness of endothelial cells to vascular endothelial growth factor and basic fibroblast growth factor added to culture media under gravity and simulated microgravity. Tissue Eng. Part A 2010, 16:1559-1573.